Investigation of the effects of various antibiotics against Klebsiella pneumoniae biofilms on in vitro catheter model

References

• Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother. 2007;51(1):78–83.10.1128/AAC.00154-06
   PubMed Web of Science ®Google Scholar
• Donlan RM. Biofilms on central venous catheters: is eradication possible? Curr Topics Microbiol Immunol. 2008;322:133–61.
   PubMed Web of Science ®Google Scholar
• Lee MY, Ko KS, Song JH. In vitro effectiveness of the antimicrobial lock techique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother. 2007;60:782–87.10.1093/jac/dkm295
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines fort he diagnosis and management of intravascular catheter related infection: 2009 update by the infectious diseases society of America. IDSA Guidelines for intravascular catheter related infection. Clin Infect Dis. 2009;49:1–45.10.1086/599185
   PubMed Web of Science ®Google Scholar
• Özbek Çelik B, Mataraci E. In vitro effectiveness of colistin, tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains. J Antimicrob Chemother. 2013;68:827–30.
   PubMed Web of Science ®Google Scholar
• Bestul MB, VandenBussche HL. Antibiotic lock technique: review of the literature. Pharmacotherapy. 2005;25:211–27.10.1592/phco.25.2.211.56947
   PubMed Web of Science ®Google Scholar
• Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother. 2003;47:3145–8.10.1128/AAC.47.10.3145-3148.2003
   PubMed Web of Science ®Google Scholar
• Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections cased by staphylococci. J Antimicrob Chemother. 2006;57:1110–5.10.1093/jac/dkl098
   PubMed Web of Science ®Google Scholar
• Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32(9):1249–72.10.1086/320001
   PubMed Web of Science ®Google Scholar
• Chen P, Seth AK, Abercrombie JJ, Mustoe TA, Leung KP. Activity of Imipenem against Klebsiella pneumoniae biofilms in vitro and in vivo. Antimicrob Agents Chemother. 2014;58(2):1208–13.10.1128/AAC.01353-13
   PubMed Web of Science ®Google Scholar
• Kandemir O, Oztuna V, Milcan A, Bayramoğlu A, Celik HH, Bayarslan C, et al. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin Orthop Relat Res. 2005;430:171–75.10.1097/01.blo.0000137551.45447.89
   Web of Science ®Google Scholar
• Tanaka G, Shigeta M, Komatssuzawa H, Sugai M, Suginaka H, Usui T. Effect of clarithromycin on Pseudomonas aeruginosa biofilms. Chemotheraphy. 2000;46:36–42.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Ajiki Y, Koga T, Yokota T. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Agents Chemother. 1994;38:138–41.10.1128/AAC.38.1.138
   PubMed Web of Science ®Google Scholar
• Nguyen PT, Baldeck JD, Olsson J, Marquis RE. Antimicrobial actions of benzimidazoles against oral streptococci. Oral Microbiol Immunol. 2005;20:93–100.10.1111/omi.2005.20.issue-2
   PubMedGoogle Scholar
• Sjostrom JE, Kuhler T, Larsson H. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother. 1997;41:1797–801.
   PubMed Web of Science ®Google Scholar
• Singh V, Arora V, Alam JM, Garey KW. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(8):4360–4.10.1128/AAC.00544-12
   PubMed Web of Science ®Google Scholar
• Naparstek L, Carmeli Y, Navon-Venezia S, Banin E. Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2014;69(4):1027–34.10.1093/jac/dkt487
   PubMed Web of Science ®Google Scholar
• Available from: https://www.lgcstandards-atcc.org/Products/All/700603.aspx#generalinformation
   Google Scholar
• O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49–79.10.1146/annurev.micro.54.1.49
   PubMed Web of Science ®Google Scholar
• Durham-Colleran MW, Verhoeven AB, van Hoek ML. Francisella novicida forms in vitro biofilms mediated by an orphan response regulator. Microb Ecol. 2010;59:457–65.10.1007/s00248-009-9586-9
   PubMed Web of Science ®Google Scholar
• European Committe on Antimicrobial Susceptibility Testing (EUCAST) Standards. Breakpoints tables for interpretation of MICs and zone diameters Version 5.0 2015.
   Google Scholar
• Aslam S, Trautner BW, Ramanathan V, et al. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother. 2007;51:1556–8.10.1128/AAC.00893-06
   PubMed Web of Science ®Google Scholar
• Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram negative or Gram positive bacilli bloodstream infections. Diagn Microbiol Infect Dis. 2009;63:208–12.10.1016/j.diagmicrobio.2008.10.004
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for determining a bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne (PA): NCCLS; 1999.
   Google Scholar
• Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist. 2014;7:343–63.
   PubMed Web of Science ®Google Scholar
• Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, et al. Management of hemodialysis catheter related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 2002;61:1136–42.10.1046/j.1523-1755.2002.00201.x
   PubMed Web of Science ®Google Scholar
• Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant. 2004;19:1237–44.10.1093/ndt/gfh041
   PubMed Web of Science ®Google Scholar
• Santarpıa L, Pasanısı F, Alfonsı L, Vıolante G, Tıseo D, De Sımone G, et al. Prevention and treatment of implanted central venous catheter (CVC)-related sepsis: a report after six years of home parenteral nutriton (HPN). Clin Nutr. 2002;21:207–11.10.1054/clnu.2002.0541
   PubMed Web of Science ®Google Scholar
• Tre-Hardy M, Traore H, El Mansossouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ. Evaluation of long term co-administration of tobramycin and clarithromycin in mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2009;34(4):370–74.10.1016/j.ijantimicag.2009.04.010
   PubMed Web of Science ®Google Scholar
• Walters 3rd MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47(1):317–23.10.1128/AAC.47.1.317-323.2003
   PubMed Web of Science ®Google Scholar
• Eng RHK, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother. 1991;35:1824–28.10.1128/AAC.35.9.1824
   PubMed Web of Science ®Google Scholar
• Chu DT, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989;33:131–35.10.1128/AAC.33.2.131
   PubMed Web of Science ®Google Scholar
• Vuotto C, Longo F, Balice MP, Donelli G, Varaldo PE. Antibiotic resistance related to biofilm formation in Klebsiella pneumoniae. Pathogens. 2014;3:743–58.10.3390/pathogens3030743
   PubMedGoogle Scholar
• Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter related sepsis. J Antimicrob Chemother. 2003;51:849–55.10.1093/jac/dkg179
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470–80.10.1093/jac/dki248
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005;41(s5):S315–32.10.1086/cid.2005.41.issue-s5
   PubMedGoogle Scholar
• Wentao N, Cai X, Liang B, Cai Y, Cui J, Wang R. Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathoens. PLoS One. 2014;9(1):e86715.
   PubMed Web of Science ®Google Scholar
• Foresti S, Di Bella S, Rovelli A, Sala A, Verna M, Bisi L, Nisii C, Gori A. Tigecycline lock therapy for catheter-related bloodstream infection caused by KPC-producing Klebsiella pneumoniae in two pediatric hematological patients. Antimicrob Agents Chemother. 2015;59(12):7919–20.10.1128/AAC.01855-15
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Noh JY, Kim WJ. In vitro comparison of anti-biofilm effects against carbapenem-resistant Acinetobacter baumannii: imipenem, colistin, tigecycline, rifampicin and combinations. Infect Chemother. 2015;47(1):27–32.10.3947/ic.2015.47.1.27
   PubMed Web of Science ®Google Scholar
• Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol. 2008;74:7376–82.10.1128/AEM.01310-08
   PubMed Web of Science ®Google Scholar
• Poudyal A, Howden BP, Bell J, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug –resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:1311–18.10.1093/jac/dkn425
   PubMed Web of Science ®Google Scholar
• Haagensen JA, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol. 2007;189:28–37.10.1128/JB.00720-06
   PubMed Web of Science ®Google Scholar
• Pamp SJ, Gjermansen M, Johansen HK, Nielsen TT. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008;68(1):223–40.10.1111/j.1365-2958.2008.06152.x
   PubMed Web of Science ®Google Scholar
• Özbek Çelik B, Mataraci Kara E. Comparative in vitro efficacies of various antipseudomonal antibiotics based catheter lock solutions on eradication of Pseudomonas aeruginosa biofilms. J Chemother. 2014;25:1–5.
   Google Scholar